In a 286-patient Phase 2 trial, elraglusib combined with gemcitabine/nab-paclitaxel achieved a statistically significant ...

Johnson & Johnson’s Oncology Care Index reveals 73% of oncologists see a gap between new cancer treatments and clinical ...

Phase III POTOMAC trial showed that adding Durvalumab (Imfinzi) to BCG induction and maintenance therapy significantly ...

For the first time, the FDA completed a generative AI-assisted scientific review pilot, cutting review tasks from days to ...

The Phase III DESTINY-Breast11 trial showed Enhertu followed by THP significantly improved pathologic complete response (pCR) ...

The first AI-powered companion diagnostic for non-small cell lung cancer has received FDA Breakthrough Device Designation.

The phase II ROME trial demonstrated that personalized therapy guided by combined tissue and liquid biopsies significantly ...

Researchers from Karolinska Institutet developed a non-invasive urine test for early prostate cancer detection, utilizing AI, ...

Zongertinib, an oral HER2-selective TKI, demonstrated a 71% objective response rate and 96% disease control in HER2-mutant ...

Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical ...

The US FDA has cleared the investigational new drug (IND) application to begin clinical trials for BFB-101, a novel gene ...